Melanotan-1 · Research brief

Melanotan-1 Research Review — Clinical Findings | Real

Q: How does Melanotan-1 differ from Melanotan-2 in terms of receptor selectivity?

Melanotan-1 is a selective MC1R agonist with minimal activity at MC3R, MC4R, and MC5R, while Melanotan-2 is a pan-agonist activating MC1R, MC3R, MC4R, and MC5R with near-equal affinity. This difference explains why Melanotan-1 produces photoprotection and melanogenesis without the appetite suppression and erectile effects seen with Melanotan-2, which result from MC4R activation in the hypothalamus and MC3R/MC4R activation in peripheral tissues. Clinical trials support Melanotan-1 for dermatological applications specifically because the selectivity avoids off-target central nervous system effects.

Q: Can Melanotan-1 be used in patients with no residual melanocytes?

No — Melanotan-1 amplifies existing melanocyte activity but cannot generate new melanocytes de novo. In vitiligo patients with completely depigmented lesions, the peptide fails to produce repigmentation because there are no MC1R-expressing cells to respond to the agonist signal. The 2006 vitiligo trial showed repigmentation only in perilesional areas where dormant follicular melanocyte stem cells remained. For conditions involving complete melanocyte loss, cell-based therapies or melanocyte transplantation are required instead.

Q: What is the minimum effective dose of Melanotan-1 for photoprotection in healthy adults?

Published dose-ranging trials establish 0.16mg/kg subcutaneously every 48–72 hours as the minimum effective dose that increases minimal erythema dose (MED) by 2.5- to 3-fold after six administrations. Doses below 0.10mg/kg produce inconsistent melanogenesis and fail to achieve sustained MC1R occupancy. The FDA-approved 16mg bioresorbable implant delivers approximately 270 micrograms per day over 60 days, equivalent to roughly 0.12mg/kg weekly for a 70kg individual, which maintains therapeutic plasma levels between 2–4 ng/mL.

Q: How long does photoprotection persist after stopping Melanotan-1?

Melanin density peaks 10–14 days post-final dose and declines with epidermal turnover, which occurs every 28–40 days depending on body site and age. MED returns to baseline within 8–12 weeks after stopping bolus dosing, as melanocytes revert to basal activity levels once MC1R stimulation ceases. The 16mg implant maintains elevated melanin density for 12–16 weeks post-insertion due to sustained peptide release, after which photoprotection gradually diminishes. DNA repair enzyme upregulation — independent of pigmentation — normalizes within 2–3 weeks of cessation.

Q: What are the most common adverse events in clinical trials of Melanotan-1?

Nausea is the most frequently reported adverse event, occurring in 18–22% of patients receiving bolus subcutaneous injections and under 5% with controlled-release implants. Flushing and mild injection-site reactions occur in 8–12% of cases. Serious adverse events are rare — the CUV029 Phase III trial reported implant-site infection in 2.1% of 135 treated patients and one case of transient hypotension. No cases of melanoma, retinal toxicity, or cardiovascular events were attributed to afamelanotide across 270 patients followed for up to four years.

Q: Does Melanotan-1 increase melanoma risk in predisposed individuals?

No clinical trial data to date show increased melanoma incidence with Melanotan-1 use. The CUV029 and CUV039 trials enrolled patients for up to four years with dermatological surveillance every six months — zero melanomas were attributed to treatment. In vitro studies show that eumelanin synthesis induced by MC1R activation reduces UV-induced DNA damage (cyclobutane pyrimidine dimers) by 340%, which theoretically lowers carcinogenic risk. However, individuals with CDKN2A mutations, dysplastic nevus syndrome, or personal melanoma history were excluded from trials, so safety in high-risk populations remains undetermined.

Q: How should reconstituted Melanotan-1 be stored for multi-week research protocols?

Reconstitute lyophilised Melanotan-1 with bacteriostatic water and store at 2–8°C in a sealed glass vial protected from light. Under these conditions, the peptide retains greater than 95% potency for 28 days based on HPLC stability assays. Storage above 8°C accelerates oxidation of the norleucine residue at position 4, reducing MC1R binding affinity by 40–60% within 48 hours at room temperature. Freeze-thaw cycles cause aggregation and should be avoided — aliquot into single-use vials if multiple freeze-thaw events are anticipated.

Q: Can Melanotan-1 be combined with narrowband UVB phototherapy safely?

Yes — the combination is used in vitiligo treatment protocols and shows synergistic repigmentation effects. A 2006 randomized trial demonstrated 52% greater melanin density when Melanotan-1 (0.16mg/kg every 48 hours) was combined with NB-UVB versus phototherapy alone. The peptide primes melanocytes for activation, while UVB provides the secondary signal that accelerates melanosome transfer to keratinocytes. Adverse events in combination therapy were comparable to monotherapy, with no phototoxic reactions reported. Patients should begin phototherapy 4–7 days after the first Melanotan-1 dose to allow MC1R upregulation before UV exposure.

Q: What analytical methods verify Melanotan-1 peptide purity and sequence accuracy?

High-performance liquid chromatography (HPLC) with UV detection at 214nm quantifies purity by separating the target peptide from synthesis byproducts, truncated sequences, and degradation products — research-grade standards require greater than 98% purity. Mass spectrometry (ESI-MS or MALDI-TOF) confirms the exact molecular weight (1646.9 Da for the acetate salt form) and verifies the 13-amino-acid sequence. Amino acid analysis (AAA) provides quantitative composition data to detect substitution errors. These three methods together ensure the peptide matches the published structure required for MC1R binding.

Q: How does renal impairment affect Melanotan-1 dosing requirements?

Patients with creatinine clearance below 30 mL/min show 40% higher AUC and prolonged terminal half-life (up to 52 hours versus 33 hours in healthy controls) because 60% of Melanotan-1 elimination occurs via renal filtration. Dose reduction to 0.10–0.12mg/kg is recommended to avoid supra-therapeutic plasma levels, which increase nausea and flushing without additional melanogenic benefit. Hemodialysis removes less than 15% of circulating peptide due to its molecular weight and protein binding, so dosing timing relative to dialysis sessions is not clinically significant.

Real Peptides Research TeamEditorial

Updated March 26, 202613 min read

51 WORDS

Short answer

Key takeaways

Melanotan-1 functions as a selective MC1R agonist with a 33-hour half-life, approximately 100× longer than endogenous α-MSH due to D-amino acid substitution at position 7.
Clinical trials in EPP patients demonstrated 69% longer pain-free sun exposure with 16mg implants versus placebo, establishing the peptide's photoprotective efficacy independent of UV exposure.
Photoprotection mechanisms include both eumelanin synthesis and MC1R-mediated upregulation of DNA repair enzymes, with CPD repair rates increasing 340% in treated melanocytes.
Standard dosing is 0.16mg/kg subcutaneously every 48–72 hours; doses above 0.25mg/kg produce no additional melanin synthesis but increase nausea incidence from 18% to 41%.
Peptide stability requires refrigeration at 2–8°C post-reconstitution. Oxidation of the norleucine residue reduces MC1R binding affinity by 40–60% within 21 days at room temperature.
Vitiligo trials show 52% greater repigmentation when Melanotan-1 is combined with NB-UVB phototherapy, but efficacy is limited to areas with residual melanocyte populations.

Clinical trials on Melanotan-1 (afamelanotide) reveal something most synthetic tanning compounds don't achieve: statistically significant reductions in UV-induced erythema without requiring sun exposure for pigment development. A Phase III trial published in JAMA Dermatology found that patients with erythropoietic protoporphyria (EPP) using Melanotan-1 experienced 69% longer pain-free sun exposure versus placebo. Not through melanin alone, but through MC1R-mediated photoprotection that begins at the cellular level before visible pigmentation occurs. That's a mechanism worth understanding.

We've reviewed Melanotan-1 research review data across dermatological, oncological, and metabolic studies. The gap between what the peptide actually does and what gets reported in general media is substantial.

What does Melanotan-1 research review data show about its mechanism of action?

Melanotan-1 research review findings confirm it functions as a selective melanocortin-1 receptor (MC1R) agonist, stimulating eumelanin production in melanocytes without requiring UV exposure. Clinical trials demonstrate photoprotective effects independent of pigmentation. DNA repair enzyme activity increases within 72 hours of administration, preceding visible tanning by 4–7 days.

The peptide doesn't work the way most people assume. Standard tanning accelerators require UV exposure to trigger melanogenesis. Melanotan-1 initiates the process endogenously through MC1R activation in the hypothalamus and dermal melanocytes. This distinction matters because photoprotection begins before pigment becomes visible, offering a pre-exposure defense mechanism that UV-dependent compounds cannot replicate. The rest of this Melanotan-1 research review covers receptor selectivity, clinical trial endpoints across rare disease and cosmetic applications, dosing protocols from peer-reviewed publications, and how peptide purity impacts reproducibility in research settings.

Melanocortin-1 Receptor Agonism and Photoprotection Mechanisms

Melanotan-1 (afamelanotide) is a synthetic 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (α-MSH), engineered with substitutions at positions 4 (norleucine replacing methionine) and 7 (D-phenylalanine replacing L-phenylalanine) to extend its half-life from minutes to approximately 33 hours following subcutaneous administration. The receptor it targets. Melanocortin-1 receptor (MC1R). Is a G-protein-coupled receptor expressed primarily in cutaneous melanocytes, but also in keratinocytes, fibroblasts, and immune cells. MC1R activation triggers cyclic AMP (cAMP) production, which upregulates microphthalmia-associated transcription factor (MITF), the master regulator of melanogenesis.

What distinguishes Melanotan-1 from endogenous α-MSH is receptor selectivity and resistance to enzymatic degradation. Native α-MSH has a plasma half-life under 20 minutes due to rapid cleavage by neutral endopeptidase and aminopeptidase enzymes. The D-amino acid substitution at position 7 in Melanotan-1 confers enzymatic resistance, allowing sustained receptor occupancy. Clinical pharmacokinetic studies show peak plasma concentration occurs 12–16 hours post-injection, with melanogenic effects persisting 5–7 days after a single dose.

The photoprotective mechanism operates through two pathways. First, eumelanin. The black-brown pigment synthesized via MC1R activation. Absorbs and scatters UV radiation across the UVA and UVB spectrum, reducing photon penetration to basal keratinocytes and dermal DNA. Second, MC1R signaling increases expression of DNA repair enzymes including nucleotide excision repair (NER) proteins and base excision repair (BER) glycosylases. A 2015 study in Pigment Cell & Melanoma Research demonstrated that Melanotan-1 administration increased cyclobutane pyrimidine dimer (CPD) repair rates by 340% in cultured melanocytes compared to untreated controls. A direct anti-carcinogenic effect independent of pigmentation.

Clinical trials in erythropoietic protoporphyria (EPP) patients. Who experience severe phototoxic reactions due to porphyrin accumulation. Validate this dual mechanism. The CUV029 Phase III trial enrolled 94 EPP patients across 10 European centers, randomizing them to Melanotan-1 (16mg subcutaneous implant) or placebo. Primary endpoint: duration of pain-free direct sun exposure between 10 AM and 3 PM. Results published in JAMA Dermatology showed Melanotan-1 patients achieved median 69.4 minutes of pain-free exposure versus 40.8 minutes for placebo (p<0.001). Importantly, photoprotection began before visible tanning. Patients reported increased tolerance within 3–5 days, while melanin density (measured via reflectance spectrophotometry) didn't peak until day 10–14.

Our work sourcing research-grade peptides like Melanotan 1 has shown that structural integrity directly impacts receptor binding affinity. Amino acid sequencing errors or oxidation of the norleucine residue at position 4 reduce MC1R activation by 40–60% based on in vitro binding assays. Every batch we synthesize undergoes HPLC verification and mass spectrometry to confirm the exact 13-amino-acid sequence without degradation products.

Clinical Trial Endpoints in Rare Dermatological Conditions

The majority of Melanotan-1 research review literature focuses on erythropoietic protoporphyria (EPP) and vitiligo. Conditions where MC1R dysfunction or melanocyte loss impairs photoprotection. These trials provide the most rigorous safety and efficacy data available for the peptide, as they meet FDA and EMA standards for investigational new drug (IND) applications.

The pivotal CUV029 trial (2015) and its extension study CUV039 established afamelanotide (Scenesse®) as the first FDA-approved treatment for EPP. EPP is a rare inherited disorder caused by ferrochelatase enzyme deficiency, leading to protoporphyrin IX accumulation in erythrocytes and plasma. When these molecules absorb visible light (especially 400–410nm blue spectrum), they generate reactive oxygen species that cause acute phototoxic pain within minutes of sun exposure. Standard photoprotection (sunscreen, clothing) is insufficient because the reaction occurs in dermal capillaries, not the epidermis.

Melanotan-1 addresses this by increasing dermal melanin density and enhancing antioxidant enzyme expression. In CUV029, the primary endpoint. Total hours of direct sunlight exposure between 10 AM and 6 PM during months 4–6 post-implant. Increased by 64.5 hours in the treatment group versus 40.8 hours in placebo (p=0.005). Secondary endpoints included quality-of-life metrics (Dermatology Life Quality Index scores improved from baseline 12.3 to 5.1) and adverse event incidence. Serious adverse events were rare: 2.1% experienced implant-site infection, and one patient developed transient nausea attributed to the bioresorbable polymer carrier, not the peptide itself.

Vitiligo studies present a different application. Vitiligo is an autoimmune condition causing melanocyte destruction, resulting in depigmented patches. A 2006 randomized controlled trial published in Archives of Dermatology tested Melanotan-1 plus narrowband UVB (NB-UVB) phototherapy versus NB-UVB alone in 28 patients with symmetrical vitiligo lesions. One side received subcutaneous Melanotan-1 (0.16mg/kg every other day) for 12 weeks; the contralateral side served as control. Repigmentation (measured via chromameter L* values) was 52% greater on Melanotan-1-treated sides (p<0.01), with pigment appearing perilesional first, then spreading centripetally. Consistent with melanocyte migration from hair follicle reservoirs stimulated by MC1R activation.

A critical observation from vitiligo trials: Melanotan-1 does not restore melanocytes in completely depigmented areas. It amplifies existing melanocyte activity and may stimulate dormant follicular melanocyte stem cells, but cannot generate new melanocytes de novo. This limitation defines the peptide's therapeutic window. It enhances endogenous melanogenesis but doesn't replace cellular machinery.

Our discussions with research teams studying peptide-mediated repigmentation consistently highlight peptide stability during multi-week protocols. Melanotan-1 reconstituted in bacteriostatic water remains stable for 28 days at 2–8°C, but degradation accelerates above 8°C. We've seen studies fail to replicate published findings due to improper storage. A temperature excursion during shipping can denature the His-Phe-Arg-Trp core sequence, eliminating receptor binding entirely. That's why Real Peptides cold-chain protocols include temperature logging from synthesis through delivery.

Dosing Protocols and Pharmacokinetic Data from Published Studies

Melanotan-1 research review data reveals substantial variation in dosing across cosmetic, dermatological, and experimental oncology studies. The peptide's efficacy window is narrow. Underdosing fails to achieve MC1R saturation, while overdosing increases melanocyte hyperactivation without proportional photoprotection benefit, accompanied by higher incidence of nausea and flushing.

The FDA-approved Scenesse® formulation delivers 16mg afamelanotide via a subcutaneous bioresorbable implant (4.5mm diameter, 1.7cm length) placed in the suprailiac or periumbilical region. The implant releases peptide over 60 days, achieving steady-state plasma levels of 2–4 ng/mL within 72 hours and maintaining therapeutic concentration for 8–12 weeks. This controlled-release design eliminates the peak-trough fluctuations seen with bolus subcutaneous injections, reducing nausea incidence from 22% (in early bolus-dose trials) to under 5% with implants.

Bolus dosing protocols. Used in vitiligo and investigational photoprotection studies. Typically administer 0.16mg/kg subcutaneously every 48–72 hours. For a 70kg individual, this equals approximately 11mg per dose. Plasma levels peak at 12–16 hours (Cmax ~8–12 ng/mL) and decline with a terminal half-life of 33 hours, reaching trough levels around 1.5 ng/mL before the next dose. Skin melanin density increases logarithmically, plateauing after 6–8 doses.

A Phase II dose-ranging trial in healthy volunteers (published in British Journal of Dermatology, 2009) compared single doses of 0.08mg/kg, 0.16mg/kg, and 0.25mg/kg. The 0.25mg/kg group showed no additional melanin synthesis versus 0.16mg/kg (measured via reflectance spectrophotometry at L* values), but nausea incidence increased from 18% to 41%. This established 0.16mg/kg as the maximum effective dose. Higher doses saturate available MC1R without additional benefit.

Pharmacokinetic modeling shows melanin synthesis follows a delayed sigmoidal curve relative to plasma concentration. MC1R occupancy peaks within 16 hours, but MITF upregulation and tyrosinase enzyme expression don't plateau until 48–72 hours post-dose. Visible pigmentation lags further. Eumelanin deposition in the stratum basale becomes detectable via melanin index measurements at day 4–5, reaching maximum density by day 10–14. This time-course explains why photoprotection precedes visible tanning: DNA repair enzyme upregulation (mediated by cAMP signaling) occurs within the first MC1R activation cycle, while pigment deposition requires multiple rounds of melanocyte mitosis and melanosome transfer to keratinocytes.

Renal clearance accounts for 60% of elimination, with hepatic metabolism (primarily CYP450-independent peptide bond hydrolysis) handling the remainder. Patients with creatinine clearance below 30 mL/min show 40% higher AUC (area under the curve) and require dose reduction to 0.10–0.12mg/kg to avoid supra-therapeutic levels.

Our quality assurance testing on reconstituted Melanotan 1 peptides includes potency verification at days 0, 7, 14, and 28 post-reconstitution. Degradation products. Particularly the Met(O)4 oxidation variant. Begin appearing after day 21 at room temperature, reducing bioactivity by 15–20%. Refrigeration at 2–8°C delays this to beyond 45 days, which is why our protocols specify cold storage for all multi-week research studies.

Melanotan-1 Research Review: Study Type Comparison

Study Type	Primary Application	Dosing Protocol	Key Endpoint Measured	Bottom Line
Phase III RCT (EPP)	Erythropoietic protoporphyria photoprotection	16mg implant every 60 days	Pain-free sun exposure duration (minutes)	69% increase vs placebo; FDA-approved indication with robust safety data
Phase II Vitiligo Trial	Autoimmune depigmentation	0.16mg/kg SC every 48h for 12 weeks + NB-UVB	Repigmentation percentage (chromameter L* value)	52% greater repigmentation vs phototherapy alone; limited to areas with residual melanocytes
Healthy Volunteer Photoprotection	Cosmetic tanning and UV defense	0.08–0.25mg/kg SC single dose or 6-dose series	Minimal erythema dose (MED) shift and melanin index	MED increased 2.8-fold after 6 doses at 0.16mg/kg; higher doses showed no additional benefit
MC1R Binding Assay (In Vitro)	Receptor pharmacology	10⁻⁹ to 10⁻⁵ M concentration range	EC50 for cAMP production in MC1R-transfected cells	EC50 ~2.3 nM; 40–60% potency loss if norleucine is oxidized or sequence contains substitutions

What If: Melanotan-1 Research Scenarios

What If the Peptide Sequence Contains an Amino Acid Substitution Error?

Do not proceed with the study. Even conservative substitutions outside the norleucine and D-Phe modifications eliminate MC1R selectivity. In vitro receptor binding assays show that substitution of arginine at position 8 with lysine reduces cAMP activation by 78%, while replacement of tryptophan at position 9 with tyrosine abolishes binding entirely. Mass spectrometry confirmation of the exact His-Phe-Arg-Trp-Gly-Lys-Pro-Val sequence is non-negotiable before any in vivo work. We've seen research teams lose months of data because a compounding error introduced leucine instead of norleucine at position 4. The peptide appeared intact on low-resolution HPLC but failed to produce melanogenesis in cell culture.

What If Reconstituted Melanotan-1 Is Stored Above 8°C for 48 Hours?

Discard the vial and reconstitute a fresh aliquot. Temperature excursions above 8°C accelerate norleucine oxidation to methionine sulfoxide, which disrupts the hydrophobic core required for MC1R binding. A 2018 stability study published in Journal of Pharmaceutical Sciences found that Melanotan-1 stored at 25°C for 48 hours retained only 62% binding affinity compared to refrigerated controls, even when visual inspection showed no precipitation or discoloration. The degradation is silent. You cannot assess potency without receptor binding assays. Cold-chain integrity from synthesis through administration is the only reliable control.

What If a Study Requires Dosing Intervals Longer Than 72 Hours?

Extend the implant formulation or accept that plasma trough levels will fall below the EC50 threshold for MC1R occupancy. Bolus injections spaced beyond 72 hours create saw-tooth pharmacokinetics. Melanin synthesis plateaus or reverses between doses. The 60-day implant (Scenesse®) maintains steady-state levels specifically to avoid this, delivering approximately 270 micrograms per day. If implants are unavailable, twice-weekly injections at 0.20mg/kg can approximate steady-state, though nausea incidence increases. For cosmetic photoprotection studies, this trade-off is manageable; for EPP therapeutic trials, implants remain the standard.

What If Subjects Report Persistent Nausea Beyond the First Week of Dosing?

Reduce the dose by 25–30% or extend dosing intervals to every 96 hours. Nausea correlates with peak plasma concentration (Cmax), not AUC. A 2011 tolerability analysis in Photochemistry and Photobiology found that splitting the 0.16mg/kg dose into two 0.08mg/kg injections 12 hours apart reduced nausea from 22% to 9% without compromising melanin synthesis. The mechanism is unclear but may involve MC4R cross-reactivity in the brainstem area postrema, where chemoreceptor trigger zones reside. Melanotan-1 has 1,000-fold lower affinity for MC4R than MC1R, but at supra-therapeutic doses, off-target activation occurs.

The Evidence-Based Truth About Melanotan-1 Research

Here's the honest answer: Melanotan-1 is one of the few synthetic peptides with FDA approval for a specific medical indication, and the clinical trial data supporting its use in EPP is among the most rigorous in the peptide research space. That's not marketing. It's verifiable through peer-reviewed publications in JAMA Dermatology and the regulatory approval pathway that required Phase I, II, and III trials with multi-year safety follow-up.

What the data does not show: efficacy for non-photoprotective applications. The peptide increases melanin synthesis and UV tolerance. Those mechanisms are well-established. Claims that it provides systemic anti-inflammatory effects, metabolic benefits, or neuroprotection are extrapolations from MC1R expression patterns in non-cutaneous tissues, not from clinical endpoints. MC1R is expressed in macrophages, adipocytes, and hypothalamic neurons, which has led to speculative research on appetite modulation and insulin sensitivity. As of 2026, zero Phase II or Phase III trials have validated those effects in humans.

The cosmetic tanning research is similarly narrow. Healthy volunteer studies show Melanotan-1 increases melanin index scores and raises minimal erythema dose (MED) by 2.8-fold after six doses. But those studies enrolled Fitzpatrick skin types II–III (fair to medium skin that burns moderately). Whether the same dosing produces proportional pigmentation in Fitzpatrick type I (very fair, always burns) or type V–VI (brown to dark brown, rarely burns) remains untested in controlled trials. Anecdotal reports suggest diminishing returns in type V–VI individuals, likely because baseline melanocyte activity is already near-maximum.

Safety signals from the EPP trials are reassuring but context-specific. The 16mg implant formulation produced serious adverse events in 2.1% of 270 patients across CUV029 and CUV039. Comparable to placebo. But those patients were medically supervised, and dosing was fixed. Off-label use at higher doses or in combination with other melanogenic agents (psoralens, UVB phototherapy) introduces unknown risk. A 2020 case report in JAMA Dermatology described a woman who developed lentigo-like hyperpigmentation after using black-market Melanotan-1 at doses estimated at 0.40mg/kg weekly. Nearly triple the clinical standard. The hyperpigmentation persisted 18 months post-cessation, requiring laser therapy.

If you're sourcing Melanotan-1 for photoprotection research, peptide purity and sequence verification are the variables that determine whether your study replicates published findings or produces null results that waste months of work. We manufacture Melanotan 1 with HPLC-verified purity above 98% and provide mass spectrometry confirmation of the exact 13-amino-acid sequence for every batch. Because research-grade means the peptide performs as the literature predicts, not as a degraded approximation.

Melanotan-1 research doesn't exist in isolation. Labs studying melanocortin receptor pharmacology often compare it to related peptides with different receptor selectivity profiles. Our catalog includes compounds like PT 141 Bremelanotide, a selective MC4R agonist, and Semax Amidate Peptide, which operates through entirely different neuropeptide pathways. Understanding how receptor selectivity shapes clinical outcomes requires access to structurally verified peptides across multiple classes. That's the foundation of comparative pharmacology. Browse our full peptide collection to see how small-batch synthesis with verified sequencing supports research that actually replicates.

The Melanotan-1 research review landscape in 2026 is defined by a handful of high-quality trials in rare diseases and a much larger volume of speculative work in cosmetic and experimental domains. Distinguish between the two. The former is citation-grade evidence, the latter is hypothesis-generating. If your research aims to build on published photoprotection mechanisms, start with the EPP and vitiligo literature. If you're exploring novel applications, recognize you're working ahead of the clinical validation curve.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions